"We have generated solid sales momentum in the third quarter and seen a strong contribution to our financial performance from savings and efficiencies arising from our more focused organization," Sanofi CEO Olivier Brandicourt said in a statement. "As a result, we are able to increase our FY 2016 Business EPS guidance." Sanofi said EPS will grow between 3% and 5% this year at constant exchange rates, up from its previous guidance of "broadly stable." "Consensus is expecting FY2016 EPS of €5.47, which is about -3% compared to FY2015," noted Goldman Sachs on Friday. Multiple sclerosis medicines Aubagio and Lemtrada were the star performers for the quarter, posting combined sales of €446 million, up 54% on the same period last year. Sales of Sanofi's biggest selling drug, Lantus, a diabetes medicine that lost patent protection last year, continued to fall, down 9.8% to €1.39 billion, leaving it in line with analyst expectations.